Holdings
Invesco Nasdaq Biotechnology ETF
As of May 31, 2026, Invesco Nasdaq Biotechnology ETF reported 243 positions worth US$66M. Largest: Gilead Sciences, Inc., Vertex Pharmaceuticals Incorporated and Amgen Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 37,039 | US$4.98M | −11,826 | May 31, 2026 |
| Vertex Pharmaceuticals Incorporated | 11,104 | US$4.97M | −3,074 | May 31, 2026 |
| Amgen Inc. | 14,213 | US$4.79M | −3,583 | May 31, 2026 |
| Regeneron Pharmaceuticals, Inc. | 5,570 | US$3.42M | −269 | May 31, 2026 |
| Alnylam Pharmaceuticals, Inc. | 7,110 | US$2.15M | −360 | May 31, 2026 |
| Revolution Medicines, Inc. | 10,624 | US$1.67M | −314 | May 31, 2026 |
| Biogen Inc. | 7,868 | US$1.54M | −427 | May 31, 2026 |
| Illumina, Inc. | 8,197 | US$1.34M | −449 | May 31, 2026 |
| United Therapeutics Corporation | 2,350 | US$1.31M | −87 | May 31, 2026 |
| Royalty Pharma Plc | 22,968 | US$1.28M | −1,203 | May 31, 2026 |